Core Viewpoint - The company has received marketing approvals for its injectable products, Parecoxib Sodium and Pemetrexed Disodium, from regulatory authorities in the Netherlands and Saudi Arabia, enhancing its international market presence and brand image [1] Group 1 - The company's subsidiary, Seacross Pharma (Europe) Ltd., and Seacross Pharmaceuticals Ltd. have obtained marketing licenses for injectable Parecoxib Sodium and Pemetrexed Disodium [1] - The approvals from the Dutch Medicines and Health Products Regulatory Authority and the Saudi Health Products Regulatory Authority signify a strategic expansion into international markets [1] - The successful launch of these products is expected to enrich the company's product pipeline and support sustainable development in international markets [1]

Core Viewpoint - The company aims to enhance its internationalization strategy and brand influence by signing an exclusive supply agreement with GOODFELLOW PHARMA CORPORATION for the product Efparepoetin alfa in the Philippines [1][6]. Summary by Sections Agreement Overview - The board of directors approved the exclusive supply agreement with GOODFELLOW for the product Efparepoetin alfa, which is currently under registration [2]. - The agreement does not involve related party transactions or constitute a major asset restructuring [2][3]. Product Information - Efparepoetin alfa is a new biological drug intended for treating anemia in adult dialysis patients due to chronic kidney disease (CKD) and has submitted a listing application [2]. - As of June 30, 2025, the cumulative R&D investment in Efparepoetin alfa is approximately 498.92 million yuan [2]. Partner Information - GOODFELLOW PHARMA CORPORATION, established in 2004, is based in Metro Manila, Philippines, and specializes in the import and export of medical products [3][4]. - There is no related party relationship between GOODFELLOW and the company [4]. Agreement Details - GOODFELLOW is authorized as the exclusive agent in the Philippines for the registration, clinical trials, promotion, distribution, and sales of Efparepoetin alfa [4][5]. - The agreement includes provisions for product registration, with the company responsible for preparing necessary documentation and providing product samples for clinical research [5]. - The agreement is effective for five years from the date of obtaining the import drug license, with a potential five-year extension [5][6]. Impact on the Company - This transaction represents a significant step in the company's internationalization strategy, expected to generate economic benefits and enhance brand value [6][7]. - The collaboration aims to expedite the commercialization of R&D results and expand the overseas market for Efparepoetin alfa, thereby improving the company's performance [7].

汇宇制药公告，公司子公司Seacross Pharma Ltd.近期获得德国国家药品和保健品安全局以及沙特阿拉伯 健康产品监管局的上市许可，涉及唑来磷酸注射液、注射用赛替派、丙戊酸钠注射用浓溶液和注射用盐 酸苯达莫司汀等产品。这些许可有助于公司丰富国际市场产品管线，提升品牌形象，并拓展国际业务的 广度和深度。公司已进行产品上市销售的准备工作，但受市场竞争等因素影响，未来能否产生较大收入 仍具有不确定性。 ...